Pregnancy and COVID-19.
Thomas NtounisIoannis ProkopakisAntonios KoutrasZacharias N FasoulakisSavia PittokopitouAsimina ValsamakiAthanasios ChionisEvangelia KontogeorgiVasiliki LamprakiAndria PerakiAthina A SamaraSevasti-Effraimia KrouskouKonstantinos NikolettosPanagiotis PapamichalisAlexandros PsarrisVasilios PergialiotisMarianna TheodoraPanos AntsaklisAlexandros DaponteGeorgios DaskalakisEmmanuel N KontomanolisPublished in: Journal of clinical medicine (2022)
Evidence indicates that SARS-CoV-2 infection increases the likelihood of adverse pregnancy outcomes. Modifications in the circulatory, pulmonary, hormonal, and immunological pathways induced by pregnancy render pregnant women as a high-risk group. A growing body of research shows that SARS-CoV-2 infection during pregnancy is connected to a number of maternal complications, including pneumonia and intensive care unit (ICU) hospitalization. Miscarriages, stillbirth, preterm labor, as well as pre-eclampsia and intrauterine growth restriction are also among the most often documented fetal implications, particularly among expecting women who have significant COVID-19 symptoms, often affecting the timing and route of delivery. Thus, prevention of infection and pharmacological treatment options should aim to minimize the aforementioned risks and ameliorate maternal, obstetric and fetal/neonatal outcomes.
Keyphrases
- pregnancy outcomes
- pregnant women
- intensive care unit
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- mechanical ventilation
- pulmonary hypertension
- preterm birth
- polycystic ovary syndrome
- risk factors
- emergency department
- adipose tissue
- gestational age
- community acquired pneumonia
- respiratory failure
- glycemic control